Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.62 |
| ▸ | RAF1 | P04049 | 2/20 | 0.62 |
| ▸ | LYN | P07948 | 2/20 | 0.62 |
| ▸ | SRC | P12931 | 2/20 | 0.62 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.57 |
| ▸ | HCK | P08631 | 8/20 | 0.55 |
| ▸ | TNF | P01375 | 4/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.54 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.54 |
| ▸ | CIT | O14578 | 1/20 | 0.53 |
| ▸ | MUSK | O15146 | 1/20 | 0.53 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.53 |
| ▸ | STK10 | O94804 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092132 | 0.94 | MAPK14 (0.56) | ABL1RAF1LYNSRCMAPK9 | |
| SCHEMBL6772136 | 0.85 | SRC (0.61) | ABL1RAF1LYNSRCMAPK9 | |
| SCHEMBL4092797 | 0.81 | MAPK14 (0.50) | ABL1RAF1LYNSRCMAPK9 | |
| SCHEMBL29594554 | 0.81 | MAPK14 (0.72) | ABL1RAF1LYNSRCMAPK9 | |
| SCHEMBL296321 | 0.81 | MAPK14 (0.72) | ABL1RAF1LYNSRCMAPK9 | |
| SCHEMBL4088544 | 0.80 | MAPK14 (0.60) | ABL1RAF1LYNSRCMAPK9 | |
| SCHEMBL4092173 | 0.80 | ABL1 (0.59) | ABL1RAF1LYNSRCMAPK9 | |
| SCHEMBL4086703 | 0.80 | MAPK14 (0.66) | ABL1RAF1LYNSRCMAPK9 | |
| SCHEMBL4093059 | 0.79 | MAPK14 (0.57) | ABL1RAF1LYNSRCMAPK9 | |
| SCHEMBL4087767 | 0.79 | MAPK14 (0.57) | ABL1RAF1LYNSRCMAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1200411-B1 | PROCESS FOR SYNTHESIS OF HETEROARYL-SUBSTITUTED UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (US) | 2005-12-14 | — | — | EP | disclosed |
| US-6894173-B2 | Intermediates useful for synthesis of heteroaryl-substituted urea compounds, and processes of making same | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-6835832-B2 | Catalytic hydrogenation | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-12-28 | — | — | US | disclosed |
| US-6774233-B2 | AUTOIMMUNE DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-10 | — | — | US | disclosed |
| US-6753426-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20030181718-A1 | A chemical intermediate carbamate compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-09-25 | — | — | US | disclosed |
| US-20030166930-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | US | disclosed |
| US-20030166931-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | US | disclosed |
| US-6583282-B1 | Formation of a urea by reacting an aromatic carbamate with a aromatic amine | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-06-24 | — | — | US | disclosed |
| US-20030109703-A1 | Polymorph and process for preparing same | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | US | disclosed |
| EP-1200411-A2 | NOVEL PROCESS FOR SYNTHESIS OF HETEROARYL-SUBSTITUTED UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001004115-A2 | NOVEL PROCESS FOR SYNTHESIS OF HETEROARYL-SUBSTITUTED UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181718-A1 | A chemical intermediate carbamate compounds | UGT1A1, ARG1, CPS1 | ABL1 1297/4885RAF1 1178/4885LYN 3555/4885 |
| US-20030166931-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | URB2, UGT1A1, PURB | ABL1 2055/4885RAF1 1359/4885LYN 2882/4885 |
| US-20030109703-A1 | Polymorph and process for preparing same | UGT1A1, CYP1A1, CYP1B1 | ABL1 1839/4885RAF1 1377/4885LYN 3775/4885 |
| US-20030166930-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | URB2, UGT1A1, PURB | ABL1 2055/4885RAF1 1359/4885LYN 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.